Last updated on August 2019

A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression


Brief description of study

The purpose of this study is to assess the safety and tolerability of esketamine nasal spray in participants with treatment-resistant depression (TRD).

Detailed Study Description

This is an open-label (the researchers and participants know the treatment the participant is receiving) long-term extension study. The study will consist of 2 open-label Phases: 4-week Induction phase (if applicable) and Open-Label Optimization/Maintenance phase (variable). Participants will enter the study Induction Phase from ESKETINTRD3001 (NCT02417064), ESKETINTRD3002 (NCT02418585), ESKETINTRD3003 (NCT02493868), ESKETINTRD3005 (NCT02422186) and ESKETINTRD3006 (US sites only). Participants will enter the study Open-Label Optimization/Maintenance phase from ESKETINTRD3001 (NCT02417064), ESKETINTRD3002 (NCT02418585), ESKETINTRD3003 (NCT02493868) (if appropriate at week 16) or ESKETINTRD3006 (US sites only). In the Open-Label Induction Phase, participants will self-administer flexibly-dosed esketamine nasal spray. During first 4 weeks in Optimization/Maintenance Phase responder participants from the induction phase of study 54135419TRD3008, will continue on the same dose of esketamine nasal spray from the induction phase and have a weekly intranasal treatment session frequency. Participants entering the optimization/maintenance phase from study ESKETINTRD3005 will also have a weekly intranasal treatment session frequency. However, as the ESKETINTRD3005 intranasal study medication is blinded at the time of entry into the current study, the dose of esketamine nasal spray will be administered as outlined in protocol. Participants entering the optimization/maintenance phase from study ESKETINTRD3003 (Direct Entry) or ESKETINTRD3004 who were ongoing in the Optimization, Maintenance, or Optimization/Maintenance phase, respectively, will have the option to have their current intranasal dosing frequency adjusted at the time of entry into 54135419TRD3008 study and should remain on the selected frequency from week 1 to week 4. A one-time dose change will be permitted at study entry. After 4 weeks, esketamine nasal spray treatment sessions will be individualized to either once weekly or once every other week at the fixed 2-week interval (based on clinical global impression - severity [CGI-S] performed at that visit), and every 4 weeks for participants dosed at the 4 week interval. Participants safety will be monitored throughout the study.

Clinical Study Identifier: NCT02782104

Find a site near you

Start Over

Preferred Research Partners

Little Rock, AR United States
  Connect »

CMB Clinical Trials

Colton, CA United States
  Connect »

Collaborative NeuroScience Network

Garden Grove, CA United States
  Connect »

Pacific Research Partners

Oakland, CA United States
  Connect »

Sharp Mesa Vista Hospital

San Diego, CA United States
  Connect »

SF-Care, Inc

San Rafael, CA United States
  Connect »

Yale University

New Haven, CT United States
  Connect »

Meridien Research

Bradenton, FL United States
  Connect »

Sarkis Clinical Trials

Gainesville, FL United States
  Connect »

Innova Clinical Trials

Miami, FL United States
  Connect »

CNS HealthCare

Orlando, FL United States
  Connect »

APG Research, LLC

Orlando, FL United States
  Connect »

Chicago Research Center

Chicago, IL United States
  Connect »

University of Chicago

Chicago, IL United States
  Connect »

Alexian Behavioral Health Hospital

Hoffman Estates, IL United States
  Connect »

Mental Health Chicago

Schaumburg, IL United States
  Connect »

Phoenix Medical Research, Inc.

Prairie Village, KS United States
  Connect »

Lake Charles Clinical Trials

Lake Charles, LA United States
  Connect »

Pharmasite Research, Inc.

Baltimore, MD United States
  Connect »

John Hopkins Hospital

Baltimore, MD United States
  Connect »

CBH Health

Rockville, MD United States
  Connect »

Massachusetts General

Boston, MA United States
  Connect »

Boston Clinical Trials

Boston, MA United States
  Connect »

Novex Clinical Research, LLC

New Bedford, MA United States
  Connect »

Beacon Clinical Research

Quincy, MA United States
  Connect »

Adams Clinical Trials, LLC

Watertown, MA United States
  Connect »

University Of Minnesota

Minneapolis, MN United States
  Connect »

Creighton University

Omaha, NE United States
  Connect »

Neurobehavioral Research, Inc

Cedarhurst, NY United States
  Connect »

NYU School of Medicine

New York, NY United States
  Connect »

Clinilabs

New York, NY United States
  Connect »

Richmond Behavioural Associates

Staten Island, NY United States
  Connect »

University of North Carolina

Chapel Hill, NC United States
  Connect »

Carolinas Medical Center

Charlotte, NC United States
  Connect »

Clinical Trials of America

Hickory, NC United States
  Connect »

IPS Research Company

Oklahoma City, OK United States
  Connect »

Paradigm Research Professionals, LLC

Oklahoma City, OK United States
  Connect »

Scranton Counseling Center

Scranton, PA United States
  Connect »

BTC Network

Lincoln, RI United States
  Connect »

KRK Medical Research

Arlington, TX United States
  Connect »

Relaro Medical Trials

Dallas, TX United States
  Connect »

Bayou City Research, Ltd

Houston, TX United States
  Connect »

Baylor College of Medicine

Houston, TX United States
  Connect »

Grayline Research Center

Wichita Falls, TX United States
  Connect »

Instituto Nacional de Psicopatolog a

Ciudad Autonoma de Buenos Aires, Argentina
  Connect »

Instituto DAMIC

Cordoba, Argentina
  Connect »

CEN

Cordoba, Argentina
  Connect »

CENAIN

Mendoza, Argentina
  Connect »

The Lyell McEwin Hospital

Elizabeth Vale, Australia
  Connect »

Frankston Hospital

Melbourne, Australia
  Connect »

UZ Brussel

Brussel, Belgium
  Connect »

CHU de Li ge

Liège, Belgium
  Connect »

Clinline s.r.o.

Hostivice, Czechia
  Connect »

Supervize s.r.o.

Kutna Hora, Czechia
  Connect »

AD71 s.r.o.

Praha 10, Czechia
  Connect »

CHU de Clermont-Ferrand

Clermont-Ferrand Cedex 1, France
  Connect »

CHU Grenoble

La Tronche, France
  Connect »

CH Henri Laborit

Poitiers Cedex, France
  Connect »

Emovis GmbH

Berlin, Germany
  Connect »

GIT-ZNS

Berlin, Germany
  Connect »

CHU de Li ge

Liège, Belgium
  Connect »

CBH Health

Gaithersburg, MD United States
  Connect »

CHU de Li ge

Liège, Belgium
  Connect »

CHU de Li ge

Liège, Belgium
  Connect »

Instituto Nacional de Psicopatolog a

Ciudad Autonoma De Buenos Aires, Argentina
  Connect »